Would you consider pembrolizumab for a patient with microsatellite stable stage IV colon cancer with high TMB on liquid biopsy who has progressed on all standard therapies?
Answer from: Medical Oncologist at Academic Institution
The Keynote 158 study demonstrated an objective response rate of 29% in patients with MSS tumors and TMB >=10 mut/MB (Marabelle et al., PMID 32919526). FDA subsequently approved pembrolizumab treatment for patients unresectable or metastatic tumor mutational burden–high (TMB-H; ≥ 10 muta...
Sign in or Register to read more